Description Of The Chairman’s Amendment In The Nature Of A Substitute To H.R. 5688, The “Bipartisan HSA Improvement Act Of 2023"

Estimated Revenue Effects Of H.R. 5687, The “HSA Modernization Act Of 2023," Scheduled For Markup By The Committee On Ways And Means On September 28, 2023

Description Of H.R. 5687, The “HSA Modernization Act Of 2023"

Estimated Revenue Effects Of ​​​​​​​H.R. 5688, The “Bipartisan HSA Improvement Act Of 2023," Scheduled For Markup By The Committee On Ways And Means On September 28, 2023

Description Of H.R. 5688, The “Bipartisan HSA Improvement Act Of 2023"

Description Of The Chairman’s Modification To The Chairman’s Mark Of The “United States-Taiwan Expedited Double-Tax Relief Act"

Description Of The Chairman’s Mark Of The “United States-Taiwan Expedited Double-Tax Relief Act"

Background And Analysis Of The Taxation Of Income Earned By Multinational Enterprises

Present Law And Background Relating To Certain Individual Income Tax Credits

Description Of The Chairman’s Amendment In The Nature Of A Substitute To H.R. 3938, The “Build It In America Act"

Description Of The Chairman’s Amendment In The Nature Of A Substitute To H.R. 3937, The “Small Business Jobs Act"

Description Of The Chairman’s Amendment In The Nature Of A Substitute To H.R. 3936 The “Tax Cuts For Working Families Act"

Estimated Revenue Effects Of H.R. 3938, The “Build It In America Act" Scheduled For Markup By The Committee On Ways And Means On June 13, 2023

Description of H.R. 3938, The “Build It In America Act"

Estimated Revenue Effects Of H.R. 3937, The “Small Business Jobs Act" Scheduled For Markup By The Committee On Ways And Means On June 13, 2023

Description Of H.R. 3937, The “Small Business Jobs Act"

Description Of H.R. 3936, The “Tax Cuts For Working Families Act"

Description Of The Chairman’s Amendment In The Nature Of A Substitute To H.R. 3797, The “Paperwork Burden Reduction Act"

Description Of H.R. 3797, The “Paperwork Burden Reduction Act"

Overview Of The Federal Tax System As In Effect For 2023

Present Law And Economic Background Relating To Pharmaceutical Manufacturers And U.S. International Tax Policy